

Supplemental Table and Figure Index.

Supplemental Figure 1: Cumulative COVID-19 Vaccination over Time (at least one dose), By Country

Supplemental Figure 2: Cumulative probability of Vaccination over time among REPRIEVE participants, By Age

Supplemental Figure 3: Cumulative probability of Vaccination over time among REPRIEVE participants, By BMI

Supplemental Figure 4: Cumulative probability of Vaccination over time among REPRIEVE participants, By ASCVD PCE

Supplemental Figure 5: Cumulative probability of Vaccination over time among REPRIEVE participants, By Nadir CD4 Cell Count

Supplemental Figure 6: Cumulative probability of Vaccination over time among REPRIEVE participants, By Baseline CD4 Cell Count

Supplemental Figure 7: Cumulative probability of Vaccination over time among REPRIEVE participants, By Duration of ART

Supplemental Figure 8: Cumulative probability of Vaccination over time among REPRIEVE participants, By History of AIDS


Supplemental Table 1: Comparison of Country-Specific Data from Our World in Data to Data from the WHO

Supplemental Table 2: Global COVID-19 Vaccination Policies

Supplemental Table 3: Participant Characteristics by Vaccine Status as of January 1, 2021


Supplemental Table 4: List of REPRIEVE Site PIs

Supplemental Figure 1: Cumulative COVID-19 Vaccination over Time (at least one dose), By Country




REPRIVE Total Country Population Eligible Country Population

Supplemental Figure 2: Cumulative probability of Vaccination over time, By Age




Participants with no follow-up in 2021 are censored at January 1, 2021. X-axis tick marks are given at the end of a given month.

Supplemental Figure 3: Cumulative probability of Vaccination over time, By BMI




Participants with no follow-up in 2021 are censored at January 1, 2021. X-axis tick marks are given at the end of a given month.

Supplemental Figure 4: Cumulative probability of Vaccination over time, By ASCVD PCE




Participants with no follow-up in 2021 are censored at January 1, 2021. X-axis tick marks are given at the end of a given month.

Supplemental Figure 5: Cumulative probability of Vaccination over time, By Nadir CD4 Cell Count




Participants with no follow-up in 2021 are censored at January 1, 2021. X-axis tick marks are given at the end of a given month.

Supplemental Figure 6: Cumulative probability of Vaccination over time, By Baseline CD4 Cell Count




Participants with no follow-up in 2021 are censored at January 1, 2021. X-axis tick marks are given at the end of a given month.

Supplemental Figure 7: Cumulative probability of Vaccination over time, By Duration of ART



Participants with no follow-up in 2021 are censored at January 1, 2021. X-axis tick marks are given at the end of a given month.

Supplemental Figure 8: Cumulative probability of Vaccination over time, By History of AIDS



Participants with no follow-up in 2021 are censored at January 1, 2021. X-axis tick marks are given at the end of a given month.

Supplemental Table 1. Comparison of Country-Specific Data from Our World in Data to Data from the WHO

	Jan-21	Feb-21	Mar-21	Apr-21	May-21	Jun-21	Jul-21
Botswana – OWD	0%	0%	0%	2%	6%	7%	10%
Botswana – WHO				2%	2%	7%	11%
Brazil - OWD	1%	3%	6%	13%	21%	33%	48%
Brazil - WHO					23%		
Canada – OWD	2%	4%	12%	31%	55%	67%	71%
Canada – WHO			29%			66%	71%
Haiti – OWD	0%	0%	0%	0%	0%	0%	<0.1%
Haiti – WHO							
India – OWD	0%	1%	4%	9%	12%	19%	25%
India – WHO				9%	14%	19%	28%
Peru – OWD	0%	1%	2%	3%	9%	13%	24%
Peru – WHO							
South Africa – OWD	0%	0%	0%	1%	2%	5%	10%
South Africa – WHO				0%	0%	5%	8%

Spain – OWD	3%	6%	11%	25%	38%	54%	68%
Spain – WHO			19%	30%	38%	53%	65%
Thailand – OWD	0%	0%	0%	2%	4%	10%	18%
Thailand – WHO				1%	4%	11%	20%
Uganda – OWD	0%	0%	0%	1%	1%	1%	1%
Uganda – WHO				1%	1%	2%	2%
US - OWD	7%	15%	28%	42%	50%	53%	56%
US - WHO			29%	44%	51%	55%	57%
Zimbabwe - OWD	0%	0%	1%	3%	4%	5%	11%
Zimbabwe - WHO				3%	5%	5%	11%

Supplemental Table 2: Global COVID-19 Vaccination Policies

	January 28, 2021	February 28, 2021	March 28, 2021	April 28, 2021	May 28, 2021	June 28, 2021	July 28, 2021	Vaccines Distributed in Each Country
Botswana	0	0	1	1	4	2	2	Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Brazil	3	3	3	3	4	4	4	Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Canada	3	3	3	3	4	5	5	Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Haiti	0	0	0	0	0	0	3	Johnson&Johnson, Moderna
India	2	2	3	4	4	4	4	Covaxin, Oxford/AstraZeneca, Sputnik V
Peru	0	1	3	3	3	3	4	Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
South Africa	0	1	1	2	1	3	3	Johnson&Johnson, Pfizer/BioNTech
Spain	2	2	2	2	3	3	5	Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Thailand	0	0	0	0	2	2	2	Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Uganda	0	1	1	1	3	3	3	Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
United States	1	2	2	4	5	5	5	Johnson&Johnson, Moderna, Pfizer/BioNTech
Zimbabwe	0	1	3	4	5	5	5	Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac, Sputnik V

0: No vaccine availability

1: Availability for ONE of following: key workers/ clinically vulnerable groups / elderly groups

2: Availability for TWO of following: key workers/ clinically vulnerable groups / elderly groups

3: Availability for ALL of following: key workers/ clinically vulnerable groups / elderly groups

4: Availability for all three plus partial additional availability (select broad groups/ages)

5: Universal availability

Vaccine Key

Two-dose vaccines: Moderna, Pfizer/BioNTech, Covaxin, Sinovac, Sputnik V, Sinopharm/Beijing

One-dose vaccines: Oxford/AstraZeneca, Johnson&Johnson

Data from Our World in Data and the WHO

Ritchie H, Mathieu E, Rodés-Guirao L, et al. Coronavirus Pandemic (COVID-19). Our World in Data. 2020

WHO COVID-19 Vaccination Dashboard

Supplemental Table 3. Participant Characteristics by Vaccine Status as of January 1, 2021

Characteristic		Total (N=6952)
Demographics		
GBD Super Region	High Income	3,450 (50%)
	Latin America and Caribbean	1,352 (19%)
	S.East/East Asia	582 (8%)
	South Asia	469 (7%)
	Sub-Saharan Africa	1,098 (16%)
Country of Enrollment	USA	3,161 (45%)
	Brazil	1,042 (15%)
	Thailand	582 (8%)
	South Africa	527 (8%)
	India	469 (7%)
	Botswana	273 (4%)
	Spain	198 (3%)
	Uganda	175 (3%)
	Peru	142 (2%)
	Haiti	136 (2%)
	Canada	123 (2%)
	Zimbabwe	123 (2%)
	Age (years)	Median (Q1,Q3)
10%,90%		42,59
40-49		3,307 (48%)
	50-59	3,029 (44%)
	60+	616 (9%)
Natal sex	Female	2,212 (32%)
Race ²	White	2,336 (34%)
	Black or African American	3,020 (43%)
	Asian	1,087 (16%)
	Other	509 (7%)
Ethnicity ³	Hispanic or Latino	1,820 (26%)
	Not Hispanic or Latino	4,840 (70%)
	Unknown	292 (4%)

Characteristic		Total (N=6952)
Cardiovascular and Metabolic		
Diabetes		60 (1%)
Hypertension		2,494 (36%)
BMI (kg/m ²)	<18.5	265 (4%)
	18.5-24.9	2,814 (41%)
	25-29.9	2,378 (34%)
	30+	1,489 (21%)
ASCVD risk score (%)	0-<2.5	1,922 (28%)
	2.5-<5	1,843 (27%)
	5-10	2,680 (39%)
	>10	507 (7%)
Smoking status	Current	1,674 (24%)
	Former	1,693 (24%)
	Never	3,578 (52%)
Comorbid Conditions		
History of cancer		261 (4%)
History of non-AIDS cancer		137 (2%)
History of kidney disease		26 (<0.5%)
Chronic active HBV		185 (3%)
Chronic active HCV		121 (2%)
HIV-Related Health History		
Total ART use duration (years)	<5	1,539 (22%)
	5-10	2,059 (30%)
	10+	3,352 (48%)
	Unknown	2 (<0.5%)
Mode of HIV Acquisition	Heterosexual Contact	3,638 (52%)
	Homosexual Contact	2,415 (35%)
	Injection Drug Use	159 (2%)
	Multiple Modes	241 (3%)
	Other	90 (1%)

Characteristic		Total (N=6952)
	Unknown	405 (6%)
History of AIDS-defining event		1,717 (25%)
Nadir CD4 count (cells/mm ³)	<50	1,263 (18%)
	50-199	2,181 (31%)
	200-349	1,815 (26%)
	350+	1,486 (21%)
	Unknown	207 (3%)
CD4 count (cells/mm ³)	<350	943 (14%)
	350-499	1,285 (18%)
	500+	4,724 (68%)
HIV-1 RNA	<LLQ	4,680 (88%)
	LLQ -< 400	518 (10%)
	400+	111 (2%)

Abbreviations: GBD, global burden of disease; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); ASCVD, atherosclerotic cardiovascular disease; AIDS, acquired immunodeficiency syndrome; HBV, hepatitis B virus; HCV, hepatitis C virus; ART, antiretroviral therapy; HIV, human immunodeficiency virus; RNA, ribonucleic acid

Supplemental Table 4: REPRIEVE Site PIs

Clinical Research Site	Clinical Research Site Leader
Abbott Northwestern Hospital CRS	Rhame, Frank
AHF-The Kinder Medical Group CRS	Kinder, Clifford
AIDS Research and Treatment Center of the Treasure Coast CRS	Pierone Jr., Gerald
Alabama CRS	Heath, Sonya
Augusta University Research Institute, Inc. CRS	MacArthur, Rodger
Barranco CRS	Lama, Javier
Baystate Infectious Diseases Clinical Research CRS	Skiest, Daniel
Bluegrass Care Clinic/University of Kentucky Research Foundation CRS	Thornton, Alice
Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS	Sax, Paul

Byramjee Jeejeebhoy Medical College (BJMC) CRS	Mave, Vidya
CAPRISA eThekweni CRS	Padayatchi, Nesri
Case Clinical Research Site	Jacobson, Jeffrey
Centre for the AIDS Programme of Research in South Africa CRS	Naidoo, Kogieleum
Centre hospitalier de l'Université Laval CRS	Trottier, Sylvie
Centro de Pesquisas Clínicas IC-HCFMUSP CRS	Kallas, Esper
Centro de Referencia e Treinamento DST/AIDS CRS	Madruga, José Valdez
Chapel Hill CRS	Wohl, David
Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS	Supparatpinyo, Khuanchai
Chronic Viral Illness Service CRS	Falutz, Julian
Cincinnati Clinical Research Site	Fichtenbaum, Carl
Columbia P&S CRS	Sobieszczyk, Magdalena
Community AIDS Network/Comprehensive Care Clinic CRS	Schreibman, Tanya

Cooper Univ. Hosp. CRS	Baxter, John
Dallas VA Medical Center CRS	Bedimo, Roger
Denver Public Health CRS	Gardner, Edward
Department of Internal Medicine, University of Iowa Hospitals & Clinics CRS	Stapleton, Jack
Division of Infectious Diseases Clinical Research Center- Drexel University CRS	Szep, Zsofia
Duke University Medical Center CRS	Okeke, Nwora
Durban International Clinical Research Site CRS	Laloo, Umesh
Eisenhower Health Center at Rimrock CRS	Lichtenstein, Kenneth
FAMCRU CRS	Cotton, Mark
Florida Department of Health – Hillsborough County	Somboonwit, Charurut
Gaborone CRS	Omoz-Oarhe, Ayotunde
Georgetown University CRS (GU CRS)	Kumar, Princy
GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS	Severe, Patrice

Greensboro CRS	Van Dam, Cornelius
Hamilton Health Sciences – Special Immunology Services Clinic CRS	Smieja, Marek
Harbor-UCLA CRS	Daar, Eric
Henry Ford Hosp. CRS	Markowitz, Norman
HGNI HIV Family Care Clinic - HHFCC CRS	da Silva Pilotto, Jose
Hospital Federal dos Servidores do Estado CRS	Joao Filho, Esau
Hospital Nossa Senhora da Conceicao CRS	Santos, Breno
Houston AIDS Research Team CRS	Arduino, Roberto
Indiana University Infectious Diseases Research CRS	Gupta, Samir
Infectious Disease Clinical and Translational Research Center (CTRC) CRS	Aberg, Judith
Inova Heart and Vascular Institute CRS	deFilippi, Christopher
Instituto de Infectologia Emilio Ribas CRS	Pereira Jr., Luiz Carlos
Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS	Grinsztejn, Beatriz

James J Peters VA Medical Center CRS	Brown, Sheldon
Johns Hopkins University CRS	Dooley, Kelly
Joint Clinical Research Centre (JCRC)/Kampala Clinical Research Site	Mutuluuza, Cissy Kityo
Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS	Rouzier, Vanessa
Los Angeles LGBT Center CRS	Bolan, Robert
Malcom Randall VA Medical Center CRS	Wang, Gary
Maple Leaf Research CRS	Smith, Graham
Massachusetts General Hospital CRS (MGH CRS)	Gandhi, Rajesh
Medical College of Wisconsin, Inc. CRS	Frank, Michael
Medical University of South Carolina: Division of Infectious Diseases CRS	Eckard, Allison
Michael E. DeBakey VAMC REPRIEVE CRS	Rodriguez-Barradas, Maria
Milton Park CRS	Borok, Margaret
Mount Sinai Beth Israel CRS	Aberg, Judith

Mount Sinai Downtown CRS	Cespedes, Michelle
Mount Sinai St. Luke's Morningside CRS	Abrams-Downey, Alexandra
Mount Sinai West Samuels CRS	Kojic, Erna (Milu)
New Jersey Medical School Clinical Research Center CRS	Swaminathan, Shobha
Northwestern University CRS	Taiwo, Babafemi
Ohio State University CRS	Koletar, Susan
Oklahoma State University Center for Health Sciences CRS	Baker, Damon
Orlando Immunology Center CRS	DeJesus, Edwin
Penn Therapeutics, CRS	Tebas, Pablo
Positive Health Clinic CRS	Hsiao, Chiu-Bin
Projeto Praça Onze Pesquisa em Saúde CRS	Schechter, Mauro
Puerto Rico AIDS Clinical Trials Unit CRS	Santana-Bagur, Jorge
Rush University CRS	Sha, Beverly
Rustenburg CRS	Brumskine, William

San Miguel CRS	Gonzales Saenz, Pedro Augusto
School of Medicine, Federal University of Minas Gerais CRS	Pinto, Jorge
Soweto ACTG CRS	Mohapi, Lerato
Specialty Care Center CRS	Bares, Sara
Stanford AIDS Clinical Trials Unit CRS	Grant, Philip
Thai Red Cross AIDS Research Centre (TRC-ARC) CRS	Avihingsanon, Anchalee
The Miriam Hospital Clinical Research Site (TMH CRS) CRS	Tashima, Karen
The Ponce de Leon Center CRS	Del Rio, Carlos
Toronto General Hospital CRS	Walmsley, Sharon Lynn
Trinity Health and Wellness Center CRS	Bedimo, Roger
Tropical Medicine Foundation Dr. Heitor Vieira Dourado CRS	Guimaraes de Lacerda, Marcus
Tufts Medical Center CRS	Wurcel, Alysse
Tulane - Louisiana Community AIDS Research Program (T- LaCARP) CRS	Mushatt, David
UCLA CARE Center CRS	Landovitz, Raphael

UCSD Antiviral Research Center CRS	Little, Susan
UCSF HIV/AIDS CRS	Havlir, Diane
UIC Project WISH CRS	Novak, Richard
University of Arizona CRS	Connick, Elizabeth
University of Cape Town Lung Institute (UCTLI) CRS	Dawson, Rodney
University of Colorado Hospital CRS	Campbell, Thomas
University of Miami Infectious Disease Research Unit at Jackson Memorial Hospital CRS	Castro, Jose
University of Mississippi Medical Center CRS	Brock, James
University of Pittsburgh CRS	Riddler, Sharon
University of Rochester Adult HIV Therapeutic Strategies Network CRS	Keefer, Michael
University of Southern California CRS	Dube, Michael
University of Toledo Medical Center CRS	Duggan, Joan

University of Washington AIDS CRS	Collier, Ann
UT Southwestern HIV/ID Clinical Trials Unit CRS	Jain, Mamta
VA West Los Angeles Medical Center CRS	Goetz, Matthew
Vancouver ID Research & Care Centre Society CRS	Conway, Brian
Vanderbilt Therapeutics (VT) CRS	Haas, David
Virginia Commonwealth University CRS	Nixon, Daniel
Wake Forest Baptist Medical Center CRS	Wilkin, Aimee
Washington University Therapeutics (WT) CRS	Presti, Rachel
Weill Cornell Chelsea CRS	Marks, Kristen
Weill Cornell Uptown CRS	Glesby, Marshall
Whitman-Walker Health CRS	Henn, Sarah
Wits Helen Joseph Hospital CRS (Wits HJH CRS)	Badal-Faesen, Sharlaa
Yale University CRS	Seval, Nikhil